Verrica Historical Financial Ratios

VRCA Stock

USD 1.28 0.04 3.23%

Verrica Pharmaceuticals is promptly reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 68.01, Dividend Yield of 0.0, PTB Ratio of 17.63 or Days Sales Outstanding of 330 will help investors to properly organize and evaluate Verrica Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

About Verrica Financial Ratios Analysis

Verrica PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Verrica Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Verrica financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Verrica Pharmaceuticals history.

Verrica Pharmaceuticals Financial Ratios Chart

At present, Verrica Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 17.63, whereas Book Value Per Share is forecasted to decline to 0.41.

Price To Sales Ratio Days Sales Outstanding Ev To Sales Debt To Equity Revenue Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Verrica Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Verrica Pharmaceuticals sales, a figure that is much harder to manipulate than other Verrica Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Debt To Equity

A measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most ratios from Verrica Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Verrica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.At present, Verrica Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 17.63, whereas Book Value Per Share is forecasted to decline to 0.41.

	2023	2024 (projected)
Graham Number	3.81	4.61
Receivables Turnover	1.16	1.1

Graham Number Receivables Turnover

Verrica Pharmaceuticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		0.34	0.99	-0.11	-0.23	-0.29	-0.44	0.34	0.99	-0.28	-0.74	0.99	-0.46	0.99	-0.02	0.07	0.09	0.34	0.36	0.69	0.34	-0.4	-0.31	-0.81	0.34	0.35
Ptb Ratio	0.34		0.39	0.52	-0.76	-0.81	-0.72	1.0	0.3	-0.81	-0.72	0.39	-0.81	0.39	0.52	-0.28	0.49	0.96	0.82	0.55	0.96	-0.72	-0.04	-0.78	0.96	0.95
Days Sales Outstanding	0.99	0.39		-0.1	-0.33	-0.31	-0.51	0.39	0.96	-0.29	-0.79	1.0	-0.48	1.0	0.11	-0.09	0.08	0.39	0.42	0.77	0.39	-0.47	-0.35	-0.84	0.39	0.41
Book Value Per Share	-0.11	0.52	-0.1		-0.61	-0.72	-0.17	0.52	-0.11	-0.73	-0.21	-0.1	-0.56	-0.1	0.11	-0.03	0.95	0.6	0.61	0.04	0.6	-0.17	0.1	-0.16	0.61	0.6
Free Cash Flow Yield	-0.23	-0.76	-0.33	-0.61		0.79	0.75	-0.76	-0.15	0.79	0.76	-0.33	0.82	-0.33	-0.78	0.63	-0.61	-0.88	-0.92	-0.62	-0.88	0.75	0.38	0.66	-0.88	-0.89
Operating Cash Flow Per Share	-0.29	-0.81	-0.31	-0.72	0.79		0.73	-0.81	-0.28	1.0	0.73	-0.31	0.96	-0.31	-0.43	0.08	-0.72	-0.91	-0.94	-0.42	-0.91	0.75	0.22	0.68	-0.91	-0.92
Capex To Depreciation	-0.44	-0.72	-0.51	-0.17	0.75	0.73		-0.72	-0.38	0.72	0.9	-0.51	0.81	-0.51	-0.75	0.45	-0.14	-0.82	-0.87	-0.79	-0.82	1.0	0.39	0.81	-0.81	-0.83
Pb Ratio	0.34	1.0	0.39	0.52	-0.76	-0.81	-0.72		0.3	-0.81	-0.72	0.39	-0.81	0.39	0.52	-0.28	0.49	0.96	0.82	0.55	0.96	-0.72	-0.04	-0.78	0.96	0.95
Ev To Sales	0.99	0.3	0.96	-0.11	-0.15	-0.28	-0.38	0.3		-0.27	-0.68	0.96	-0.43	0.96	-0.13	0.19	0.1	0.29	0.31	0.61	0.29	-0.33	-0.27	-0.77	0.29	0.3
Free Cash Flow Per Share	-0.28	-0.81	-0.29	-0.73	0.79	1.0	0.72	-0.81	-0.27		0.72	-0.29	0.96	-0.29	-0.43	0.08	-0.73	-0.91	-0.94	-0.4	-0.91	0.74	0.22	0.67	-0.91	-0.91
Roic	-0.74	-0.72	-0.79	-0.21	0.76	0.73	0.9	-0.72	-0.68	0.72		-0.79	0.86	-0.79	-0.59	0.36	-0.3	-0.81	-0.85	-0.84	-0.81	0.88	0.46	0.95	-0.8	-0.82
Inventory Turnover	0.99	0.39	1.0	-0.1	-0.33	-0.31	-0.51	0.39	0.96	-0.29	-0.79		-0.48	1.0	0.11	-0.09	0.08	0.4	0.42	0.77	0.39	-0.47	-0.36	-0.84	0.39	0.41
Net Income Per Share	-0.46	-0.81	-0.48	-0.56	0.82	0.96	0.81	-0.81	-0.43	0.96	0.86	-0.48		-0.48	-0.5	0.14	-0.62	-0.91	-0.95	-0.52	-0.91	0.82	0.37	0.82	-0.91	-0.92
Days Of Inventory On Hand	0.99	0.39	1.0	-0.1	-0.33	-0.31	-0.51	0.39	0.96	-0.29	-0.79	1.0	-0.48		0.11	-0.09	0.08	0.4	0.42	0.77	0.39	-0.47	-0.36	-0.84	0.39	0.41
Payables Turnover	-0.02	0.52	0.11	0.11	-0.78	-0.43	-0.75	0.52	-0.13	-0.43	-0.59	0.11	-0.5	0.11		-0.86	0.05	0.62	0.65	0.54	0.62	-0.77	-0.39	-0.45	0.62	0.63
Capex To Revenue	0.07	-0.28	-0.09	-0.03	0.63	0.08	0.45	-0.28	0.19	0.08	0.36	-0.09	0.14	-0.09	-0.86		0.04	-0.35	-0.37	-0.54	-0.35	0.44	0.2	0.22	-0.36	-0.36
Cash Per Share	0.09	0.49	0.08	0.95	-0.61	-0.72	-0.14	0.49	0.1	-0.73	-0.3	0.08	-0.62	0.08	0.05	0.04		0.58	0.61	0.07	0.59	-0.15	0.02	-0.28	0.59	0.59
Pocfratio	0.34	0.96	0.39	0.6	-0.88	-0.91	-0.82	0.96	0.29	-0.91	-0.81	0.4	-0.91	0.4	0.62	-0.35	0.58		0.94	0.61	1.0	-0.82	-0.18	-0.79	1.0	1.0
Interest Coverage	0.36	0.82	0.42	0.61	-0.92	-0.94	-0.87	0.82	0.31	-0.94	-0.85	0.42	-0.95	0.42	0.65	-0.37	0.61	0.94		0.65	0.94	-0.87	-0.35	-0.76	0.94	0.95
Capex To Operating Cash Flow	0.69	0.55	0.77	0.04	-0.62	-0.42	-0.79	0.55	0.61	-0.4	-0.84	0.77	-0.52	0.77	0.54	-0.54	0.07	0.61	0.65		0.61	-0.73	-0.29	-0.78	0.61	0.62
Pfcf Ratio	0.34	0.96	0.39	0.6	-0.88	-0.91	-0.82	0.96	0.29	-0.91	-0.81	0.39	-0.91	0.39	0.62	-0.35	0.59	1.0	0.94	0.61		-0.82	-0.18	-0.79	1.0	1.0
Days Payables Outstanding	-0.4	-0.72	-0.47	-0.17	0.75	0.75	1.0	-0.72	-0.33	0.74	0.88	-0.47	0.82	-0.47	-0.77	0.44	-0.15	-0.82	-0.87	-0.73	-0.82		0.41	0.79	-0.81	-0.83
Income Quality	-0.31	-0.04	-0.35	0.1	0.38	0.22	0.39	-0.04	-0.27	0.22	0.46	-0.36	0.37	-0.36	-0.39	0.2	0.02	-0.18	-0.35	-0.29	-0.18	0.41		0.4	-0.18	-0.21
Roe	-0.81	-0.78	-0.84	-0.16	0.66	0.68	0.81	-0.78	-0.77	0.67	0.95	-0.84	0.82	-0.84	-0.45	0.22	-0.28	-0.79	-0.76	-0.78	-0.79	0.79	0.4		-0.79	-0.8
Ev To Operating Cash Flow	0.34	0.96	0.39	0.61	-0.88	-0.91	-0.81	0.96	0.29	-0.91	-0.8	0.39	-0.91	0.39	0.62	-0.36	0.59	1.0	0.94	0.61	1.0	-0.81	-0.18	-0.79		1.0
Pe Ratio	0.35	0.95	0.41	0.6	-0.89	-0.92	-0.83	0.95	0.3	-0.91	-0.82	0.41	-0.92	0.41	0.63	-0.36	0.59	1.0	0.95	0.62	1.0	-0.83	-0.21	-0.8	1.0

Click cells to compare fundamentals

Verrica Pharmaceuticals Account Relationship Matchups

Verrica Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	6.09	8.72	7.6	2.35	16.79	17.63
Book Value Per Share	2.61	1.32	1.21	1.17	0.44	0.41
Free Cash Flow Yield	(0.0131)	(0.16)	(0.071)	(0.11)	(0.2)	(0.12)
Operating Cash Flow Per Share	(1.1)	(1.21)	(1.02)	(0.55)	(0.85)	(0.89)
Capex To Depreciation	2.65	6.42	1.87	0.42	0.43	0.41
Pb Ratio	6.09	8.72	7.6	2.35	16.79	17.63
Roic	(0.26)	(0.46)	(0.63)	(0.6)	(1.04)	(1.09)
Net Income Per Share	(1.12)	(1.82)	(1.44)	(0.81)	(1.48)	(1.55)
Payables Turnover	0.22	0.66	0.56	1.43	0.3	0.42
Cash Per Share	2.49	2.62	2.6	1.0	1.53	3.06
Pocfratio	(14.43)	(9.52)	(8.98)	(5.04)	(8.6)	(9.03)
Capex To Operating Cash Flow	(0.0249)	(0.0487)	(0.032)	(0.0162)	(0.009384)	(0.009853)
Pfcf Ratio	(14.08)	(9.08)	(8.7)	(4.96)	(8.52)	(8.95)
Days Payables Outstanding	1.7K	554.67	653.44	255.25	1.2K	1.1K
Income Quality	0.97	0.71	0.79	0.76	0.58	0.9
Roe	(0.43)	(1.38)	(1.19)	(0.69)	(3.39)	(3.22)
Ev To Operating Cash Flow	(14.1)	(10.34)	(9.98)	(3.28)	(7.98)	(8.38)
Pe Ratio	(14.15)	(6.32)	(6.37)	(3.39)	(4.95)	(5.2)
Return On Tangible Assets	(0.22)	(0.41)	(0.61)	(0.62)	(0.82)	(0.86)
Ev To Free Cash Flow	(13.76)	(9.86)	(9.67)	(3.23)	(7.91)	(8.3)
Earnings Yield	(0.17)	(0.0706)	(0.16)	(0.29)	(0.2)	(0.21)
Net Debt To E B I T D A	0.3	(0.62)	(0.91)	1.52	0.39	0.37
Current Ratio	19.39	1.66	1.61	11.31	4.55	4.33
Tangible Book Value Per Share	2.61	1.32	1.21	1.17	0.44	0.41
Graham Number	8.12	7.35	6.25	4.62	3.81	4.61
Shareholders Equity Per Share	2.61	1.32	1.21	1.17	0.44	0.41
Capex Per Share	0.0274	0.0588	0.0326	0.00884	0.007984	0.007585
Graham Net Net	2.35	0.97	0.84	0.87	0.25	0.24
Enterprise Value Over E B I T D A	(12.85)	(7.92)	(9.08)	(2.83)	(4.95)	(5.2)
Price Earnings Ratio	(14.15)	(6.32)	(6.37)	(3.39)	(4.95)	(5.2)
Price Book Value Ratio	6.09	8.72	7.6	2.35	16.79	17.63
Price Earnings To Growth Ratio	0.69	(0.1)	0.3	0.0776	(0.0599)	(0.0569)
Days Of Payables Outstanding	1.7K	554.67	653.44	255.25	1.2K	1.1K
Price To Operating Cash Flows Ratio	(14.43)	(9.52)	(8.98)	(5.04)	(8.6)	(9.03)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:

How To Invest In Verrica

Details

Is Verrica Stock a good investment?

Details

What is Verrica Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.84)

Revenue Per Share

0.198

Quarterly Revenue Growth

27.445

Return On Assets

(0.71)

Return On Equity

(20.60)

The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verrica Historical Financial Ratios

About Verrica Financial Ratios Analysis

Verrica Pharmaceuticals Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Debt To Equity

Revenue Per Share

Verrica Pharmaceuticals fundamentals Correlations

Verrica Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Verrica Pharmaceuticals fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Pb Ratio	+ 1.0	Ptb Ratio
Inventory Turnover	+ 1.0	Days Sales Outstanding
Days Of Inventory On Hand	+ 1.0	Days Sales Outstanding
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Days Payables Outstanding	+ 1.0	Capex To Depreciation
Days Of Inventory On Hand	+ 1.0	Inventory Turnover

Interest Coverage	- 0.95	Net Income Per Share
Interest Coverage	- 0.94	Free Cash Flow Per Share
Interest Coverage	- 0.94	Operating Cash Flow Per Share
Pe Ratio	- 0.92	Net Income Per Share
Pe Ratio	- 0.92	Operating Cash Flow Per Share
Interest Coverage	- 0.92	Free Cash Flow Yield